Literature is warming up and extending e-values to platform trials seems the logical next step.
This will allow continuous monitoring of clinical trials while controlling type I error.
arxiv.org/abs/2602.06379
arxiv.org/abs/2512.04366
arxiv.org/abs/2606.00878
Adaptive clinical trials rely on interim analyses, flexible stopping, and data-dependent design modifications that complicate statistical guarantees when fixed-horizon test statistics are repeatedly i...
